Antineoplastic agents 365. Dolastatin 10 SAR probes

George R. Pettit, Jayaram K. Srirangam, Jozsef Barkoczy, Michael D. Williams, Michael R. Boyd, Ernest Hamel, Robin K. Pettit, Fiona Hogan, Ruoli Bai, Jean Charles Chapuis, Shane C. McAllister, Jean M. Schmidt

Research output: Contribution to journalArticlepeer-review

68 Scopus citations


The remarkable anticancer drug dolastatin 10 (1a) from the Indian Ocean sea hare Dolabella auricularia is currently undergoing phase I clinical trials. Thirty-eight new structural modifications of this unusual peptide have been synthesized and evaluated against a variety of human and murine cancer cell lines, and for their ability to inhibit tubulin polymerization and vinblastine and GTP binding to tubulin. Dolastatin 10 and one structural modification was found to have antifungal activity, while one other structural modification of the parent compound exhibited antibacterial activity. Some of the new peptides approximated the antineoplastic potency of dolastatin 10, especially those based on replacement of the Doe unit with Met, Phe or an appropriately substituted phenylethylamide.

Original languageEnglish (US)
Pages (from-to)243-277
Number of pages35
JournalAnti-Cancer Drug Design
Issue number4
StatePublished - Jun 1998


  • Antineoplastic agents
  • Dolastatin 10
  • Structural modifications

Fingerprint Dive into the research topics of 'Antineoplastic agents 365. Dolastatin 10 SAR probes'. Together they form a unique fingerprint.

Cite this